Table 4.
| Author Year |
Intervention | Control | Application | Dose PEA | Duration | Primary Outcome | Secondary Outcome | AE |
|---|---|---|---|---|---|---|---|---|
| Andresen 2016 [27] |
PEA | Plc. | s.l. | 600 mg 2×/d |
12 w | No sig. differences | Rescue medication intake in PEA group sig. reduced, no sig. improvement in QoL | no |
| Cobellis 2011 [29] |
PEA + transpolydatin | Plc. or Celecoxib 200 mg 2×/d | p.o. | 400 mg 2×/d |
3 m | Sig. better pain reduction compared to placebo | Satisfaction with therapy in celecoxib and PEA group sig. higher than in placebo group | no |
| Cremon 2017 [25] |
PEA + transpolydatin | Plc. | p.o. | 200 mg 2×/d |
12 w | Sig. better pain reduction compared to placebo | General wellbeing questionnaire in both groups without sig. difference Improved, rescue medication intake without sig. differences | no |
| Faig-Marti 2017 [30] |
PEA | Plc. | p.o. | 300 mg 2×/d |
60 d | No sig. differences | no sig. differences in the two groups in function and seveity | n.r. |
| Marini 2012 [31] |
PEA | Ibuprofen 600 mg 3×/d | p.o. | (300 mg + 600 mg)/d (1–7 d), (2× 300 mg)/d (8–14 d) | 14 d | Sig. pain reduction compared to ibuprofen | Change in maximum mouth opening after therapy in PEA group sig. higher than in ibuprofen group | no |
| Murina 2013 [32] |
PEA + transpolydatin | Plc. | p.o. | 400 mg 2×/d |
60 d | Sig. pain reduction in both groups; no sig. benefit between placebo and PEA | Marinoff Dyspareuniae scale in both groups sig. improves but no sig. difference between placebo and PEA | 2 AE’s in PEA, 1 in Plc. Group (mild, transient gastrointestinal symptoms) |
| Orefice 2016 [28] |
PEA | Plc. | p.o. | 600 mg 1×/d |
12 m | Sig. better pain reduction compared to placebo | QoL with sig. improvement at 12 months compared to placebo, no sig. changes in the EDSS score | no |
| Ottaviani 2019 [33] |
PEA | Plc. | s.l. | 600 mg 2×/d |
60 d | Sig. better pain reduction compared to placebo | None | no |
| Pickering 2022 [34] |
PEA | Plc. | p.o. | 300 mg 2×/d |
8 w | Sig. improvement in neuropathic pain scale | Improved sleep quality and mood | no |
| Steels 2019 [26] |
PEA | Plc. | p.o. | 150 mg/300 mg 2×/d |
8 w | Sig. better pain reduction compared to placebo | WOMAC scores in PEA group sign. better, reduction of rescue medication, improvement in anxiety score, remaining scores unchanged | no |
| Tartaglia 2015 [35] |
PEA + transpolydatin | Plc. | p.o. | 400 mg 1×/d |
10 d | Sig. better pain reduction compared to placebo | None | no |
AE: adverse events; EDDS: expanded disability status scale; n.r.: not reported; PEA: palmitoylethanolamide; Plc: placebo; QoL: quality of life.